| 92134-98-0

• 物质功能分类: 分析化学 - 标准品 - 药典标准品和杂质标准品
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• CAS: 92134-98-0
• 化学式: C16H15N2NaO6P
• 分子量: 385.26
• InChiKey: GDNOSLQPJOZQKH-UHFFFAOYSA-N

物化性质

• 熔点：
  220° (softens)
• 溶解度：
  H2O：≥15mg/mL

计算性质

• 辛醇/水分配系数(LogP)：
  1.17
• 重原子数：
  26
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  116
• 氢给体数：
  3
• 氢受体数：
  6

安全信息

• 危险品标志：
  T
• 安全说明：
  S36/37,S45,S53
• 危险类别码：
  R45,R61,R22
• WGK Germany：
  2,3
• 海关编码：
  2933790090
• 包装等级：
  III
• 危险类别：
  6.1
• 危险性防范说明：
  P301+P310
• 危险品运输编号：
  2811
• 危险性描述：
  H301

制备方法与用途

概述

苯妥英钠注射液已广泛用于急性治疗症状性癫痫的药物。但作为急救药物，它只能用于静脉滴注，并且注射部位局部疼痛、红肿、难以忍受。1997年美国FDA停用苯妥英钠注射液，文献报道英国亦考虑停用苯妥英钠注射液。磷苯妥英钠注射液是美国WannerLambert公司开发的苯妥英钠注射液升级换代产品。磷苯妥英钠是苯妥英前体药物，它在体内经膦酸酯酶迅速水解而全部转化为苯妥英，1996年9月美国FDA批准上市，1999年在英国上市。磷苯妥英钠的水溶性是苯妥英钠的4000倍，水溶液pH值8.6～12，从而克服了苯妥英钠临床使用带来的不良反应，因而成为疗效好、安全性高、刺激性小的抗癫痫新药。

适应症

适用于急性治疗症状性癫痫以及预防和治疗进行神经手术或头部创伤病人的中风。

特点

静注磷苯妥英钠注射液注射部位难以忍受的情况仅为9%，注射过程中断率为21%，平均注射时间为13min，较苯妥英钠注射液注射部位难以忍受分别为90%，注射过程中断率67%和平均注射时间44min有了很大的提高。使必须用苯妥英钠注射液的患者又快又好地接受治疗、耐受性好、中断治疗少，不良反应少。

生物活性

Fosphenytoin (disodium)是fosphenytoin的钠盐形式，fosphenytoin是一种前体药物，在肠胃外给药可水解成具有抗惊厥作用的苯妥英。

体内研究

Fosphenytoin is an effective neuroprotectant against ischemia-induced damage. In fosphenytoin (30 mg/kg, i.m.)-treated rat 5 min after ischemia episode, hippocampal CA1 pyramidal neurons remain at near control level (13.90 +/- 0.92), however, GFAP staining iss not significantly changed. In fosphenytoin (84 mg/kg)-treated rat, the relative bioavailability of fosphenytoin is 83%. In fully kindled female Wistar rats, fosphenytoin dose-dependently increases the focal seizure (afterdischarge) threshold. Seizure severity and duration at threshold are reduced only after the highest does of fosphenytoin tested (84 mg/kg).

文献信息

• [EN] POLYBIOTIN COMPOUNDS FOR MAGNETIC RESONANCE IMAGINING AND DRUG DELIVERY<br/>[FR] COMPOSES DE POLYBIOTINE POUR IRM ET ADMINISTRATION DE MEDICAMENTS
  申请人：GEN HOSPITAL CORP

  公开号：WO2005032598A1

  公开（公告）日：2005-04-14

  The invention relates generally to biotin-containing compounds that are useful as imaging agents and drug-delivery agents. Another aspect of the invention relates to the aforementioned compounds chelated to a metal atom. In a preferred embodiment, the metal atom is a gadolinium. Another aspect of the invention relates to a compound comprising three biotin moieties and a pharmaceutical agent covalently bound to a heterocyclic core. In certain embodiments, the pharmaceutical agent is an antibiotic, antiviral, or radionuclide. Another aspect of the present invention relates to a method of treating disease involving administering the compounds of the invention to a mammal. Another aspect of the present invention relates to a method of acquiring a magnetic resonance image using the compounds of the invention.

  该发明涉及一般用作成像剂和药物传递剂的含生物素化合物。该发明的另一个方面涉及上述化合物螯合到金属原子上。在一个优选实施例中，金属原子是钆。该发明的另一个方面涉及一种包含三个生物素基团和一个与杂环核共价结合的药物剂的化合物。在某些实施例中，药物剂是抗生素、抗病毒药物或放射性核素。本发明的另一个方面涉及一种涉及向哺乳动物施用该发明化合物以治疗疾病的方法。本发明的另一个方面涉及使用该发明化合物获得磁共振图像的方法。
• CO-THERAPY FOR THE TREATMENT OF EPILEPSY AND RELATED DISORDERS
  申请人：Smith-Swintosky L. Virginia

  公开号：US20070293476A1

  公开（公告）日：2007-12-20

  The present invention is directed to a method for the treatment of epilepsy and related disorders comprising administering to a subject in need thereof, co-therapy with a therapeutically effective amount of a benzo-heteroaryl sulfamide derivative as described herein and a therapeutically effective amount of one or more anticonvulsant and/or anti-epileptic agents.

  本发明涉及一种治疗癫痫和相关疾病的方法，包括向需要的受试者施用本文描述的苯并杂环磺酰胺衍生物的治疗有效剂量，以及一种或多种抗惊厥和/或抗癫痫药物的治疗有效剂量的联合治疗。
• Multi-functional ionic liquid compositions for overcoming polymorphism and imparting improved properties for active pharmaceutical, biological, nutritional, and energetic ingredients
  申请人：Rogers D. Robin

  公开号：US20070093462A1

  公开（公告）日：2007-04-26

  Disclosed are ionic liquids and methods of preparing ionic liquid compositions of active pharmaceutical, biological, nutritional, and energetic ingredients. Also disclosed are methods of using the compositions described herein to overcome polymorphism, overcome solubility and delivery problems, to control release rates, add functionality, enhance efficacy (synergy), and improve ease of use and manufacture.

  揭示了离子液体及制备活性药物、生物、营养和能量成分的离子液体组合物的方法。还揭示了利用本文描述的组合物的方法，以克服多型性、克服溶解度和输送问题、控制释放速率、增加功能性、增强功效（协同作用）以及改善易用性和制造工艺。
• Glucuronidated nebivolol metabolites
  申请人：O'Donnell P. John

  公开号：US20070014734A1

  公开（公告）日：2007-01-18

  This invention provides glucuronidated nebivolol metabolites and pharmaceutical compositions of glucuronidated nebivolol metabolites for treatment of cardiovascular diseases. In addition, this invention also provides compositions comprising nebivolol and/or at least one glucuronidated metabolite of nebivolol and/or at least one other active compound in a pharmaceutically acceptable carrier. This invention also provides methods of treating and/or preventing vascular diseases, by administering at least one glucuronidated metabolite of nebivolol that is capable of releasing a therapeutically effective amount of nitric oxide to a targeted site affected by the vascular disease. Also, this invention is directed to the treatment and/or prevention of migraine headaches administering at least one glucuronidated metabolite of nebivolol. This invention may also be used in conjunction with or as a single treatment of metabolic syndrome disorders.

  这项发明提供了葡萄糖醛酸化的尼布ivolol代谢物以及用于治疗心血管疾病的葡萄糖醛酸化的尼布ivolol代谢物的制药组合物。此外，该发明还提供了包含尼布ivolol和/或至少一种尼布ivolol的葡萄糖醛酸化代谢物和/或至少一种其他活性化合物的药用可接受载体的组合物。该发明还提供了通过向受影响血管疾病的靶位点投与至少一种能释放治疗有效量一氧化氮的尼布ivolol的葡萄糖醛酸化代谢物来治疗和/或预防血管疾病的方法。此外，该发明旨在通过投与至少一种尼布ivolol的葡萄糖醛酸化代谢物来治疗和/或预防偏头痛。该发明还可与代谢综合征紊乱的单一治疗或联合治疗一起使用。
• Process for the preparation of sodium fosphenytoin
  申请人：Kirsch Volker

  公开号：US20050272706A1

  公开（公告）日：2005-12-08

  Phosphoric acid diester 2,5-dioxo-4,4-diphenylimidazolidin-1-ylmethyl esters, both of whose ester groups can be selectively cleaved, are obtained by converting 3-(hydroxymethyl)-5,5-diphenylimidazolidine-2,4-dione to an alkylsulfonate or arylsulfonate and reacting this with a phosphoric acid diester whose ester groups can be selectively cleaved from the reaction product. The two ester groups can be selectively cleaved from the phosphoric acid diesters obtained and the resulting product can be converted to 5,5-diphenyl-3-[(phosphonooxy)methyl]imidazolidine-2,4-dione disodium salt. The latter is an anticonvulsive, antiepileptic and antiarrhythmic known under the abbreviated name of sodium fosphenytoin.

  磷酸二酯2,5-二氧代-4,4-二苯基咪唑烷-1-甲酯，其两个酯基可选择性地被裂解，通过将3-(羟甲基)-5,5-二苯基咪唑烷-2,4-二酮转化为烷磺酸酯或芳基磺酸酯，并将其与一个磷酸二酯反应而获得。从所得的磷酸二酯中可以选择性地裂解两个酯基，得到的产物可以转化为5,5-二苯基-3-[(磷酸酯氧)甲基]咪唑烷-2,4-二酮二钠盐。后者是一种抗抽搐、抗癫痫和抗心律失常药物，简称为磷酸美多嗪钠。